Perimenopause and Bone Loss: What to Know About Osteoporosis

Perimenopause is most discussed for hot flashes and mood changes—but it is also a window when bone density can decline faster than at almost any other life stage. Because bones do not send pain signals until significant loss has already occurred, many women reach their 50s without knowing how much the transition cost them in skeletal terms.

Why perimenopause accelerates bone loss

Estrogen slows the activity of osteoclasts—the cells responsible for breaking down old bone. As estrogen fluctuates and eventually declines through the menopause transition, bone resorption begins to outpace formation. Research from the Study of Women's Health Across the Nation (SWAN) found that women can lose two to three percent of bone mineral density per year in the years around the final menstrual period, compared with less than one percent per year during stable premenopausal years. The steepest losses tend to occur in the two years before and the first two to three years after the final period—a window that overlaps heavily with late perimenopause.

Who is at higher risk

Not every woman loses the same amount of bone, and understanding your personal risk profile helps you and your clinician decide how aggressively to monitor and intervene.

• Early menopause (before age 45) or premature ovarian insufficiency (before age 40)—a longer estrogen-deficient window means more cumulative loss.
• Low body weight or significant weight-loss history—less mechanical load on bones and lower adipose estrogen production.
• Family history of hip fracture or maternal osteoporosis.
• Long-term corticosteroid use (prednisolone and related drugs suppress bone formation directly).
• Current smoking or heavy alcohol use—both impair osteoblast function.
• Consistently low calcium and vitamin D intake.
• History of eating disorder or prolonged amenorrhoea from any cause.
• Very low physical activity, particularly limited weight-bearing movement.

When to ask about a DEXA scan

DEXA (dual-energy X-ray absorptiometry) is the gold-standard tool for measuring bone mineral density. Results are expressed as T-scores: above −1.0 is normal, −1.0 to −2.5 is osteopenia, and −2.5 or below is osteoporosis. USPSTF guidelines recommend universal screening from age 65, but evidence supports earlier scanning in women with risk factors—including those approaching menopause before 45 or those with multiple items from the list above. A baseline scan in perimenopause creates a reference point; a repeat scan two to five years later quantifies the rate of change. The WHO-endorsed FRAX calculator estimates ten-year fracture probability from clinical variables alone and can be a useful first step before imaging.

Evidence-based steps to protect your bones now

Lifestyle measures reduce loss but rarely reverse significant deficits. They are most effective when started early in the transition, before substantial bone has been lost.

• Calcium: aim for 1,000–1,200 mg per day from food where possible. Dairy, fortified plant milks, tinned salmon with bones, almonds, and leafy greens are reliable sources. Supplements can fill genuine dietary gaps but are generally less well absorbed than food-based calcium.
• Vitamin D: most guidelines recommend 800–1,000 IU daily for bone health. A serum 25-OH vitamin D below 50 nmol/L is associated with increased bone loss; a blood test is straightforward and worth requesting.
• Weight-bearing aerobic activity: walking, jogging, dancing, and hiking place mechanical load on bone, stimulating osteoblast activity. Aim for at least 150 minutes per week.
• Resistance training: lifting weights or using resistance bands generates stress at bone attachment points. Two to three sessions per week slow bone loss at the hip and spine in midlife women.
• Smoking cessation and alcohol moderation: smoking is a direct bone toxin; more than seven units of alcohol per week impairs calcium absorption and bone formation.
• Fall prevention: bone density is only part of fracture risk. Balance exercises, minimising sedative medications where possible, and addressing home hazards reduce fracture risk independently of bone mineral density.

How hormone therapy relates to bone

Systemic estrogen therapy is one of the most effective interventions for preserving bone mineral density during and after the menopause transition. Estrogen receptors are present on osteoblasts, and replacing the declining estrogen signal directly attenuates osteoclast-driven resorption. Multiple large studies confirm that women using hormone therapy have significantly lower fracture rates than non-users. If you are already considering HRT for vasomotor symptoms or mood, bone protection is an additional benefit worth raising with your prescriber.

If hormone therapy is not appropriate for you, bone-specific pharmacological options—bisphosphonates such as alendronate, and agents such as denosumab—are available and should be part of the conversation once osteoporosis or high fracture risk is confirmed. These are prescription decisions requiring a full risk-benefit discussion with a clinician.